These data collectively indicate that oral administration of CRB‐2131 mitigates early pathological hallmarks of AD, including oxidative stress and Tau hyperphosphorylation, in a dose‐dependent manner in vivo. The gene discussed is MAPT; the disease is Alzheimer disease.